GENF vs. SBTX, COS, APTA, C4XD, DDDD, AREC, SAR, POLB, OKYO, and AOR
Should you be buying Genflow Biosciences stock or one of its competitors? The main competitors of Genflow Biosciences include SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), Aptamer Group (APTA), C4X Discovery (C4XD), 4D pharma (DDDD), Arecor Therapeutics (AREC), Sareum (SAR), Poolbeg Pharma (POLB), OKYO Pharma (OKYO), and AorTech International (AOR). These companies are all part of the "biotechnology" industry.
Genflow Biosciences vs. Its Competitors
Genflow Biosciences (LON:GENF) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.
Genflow Biosciences has higher earnings, but lower revenue than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Genflow Biosciences had 3 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 3 mentions for Genflow Biosciences and 0 mentions for SkinBioTherapeutics. Genflow Biosciences' average media sentiment score of 0.27 beat SkinBioTherapeutics' score of 0.00 indicating that Genflow Biosciences is being referred to more favorably in the media.
2.7% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 3.4% of SkinBioTherapeutics shares are owned by institutional investors. 42.8% of Genflow Biosciences shares are owned by company insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Genflow Biosciences has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.
Genflow Biosciences has a net margin of 778.46% compared to SkinBioTherapeutics' net margin of -237.95%. SkinBioTherapeutics' return on equity of -115.86% beat Genflow Biosciences' return on equity.
Summary
Genflow Biosciences beats SkinBioTherapeutics on 9 of the 12 factors compared between the two stocks.
Get Genflow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GENF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genflow Biosciences Competitors List
Related Companies and Tools
This page (LON:GENF) was last updated on 10/14/2025 by MarketBeat.com Staff
